Wick, M., Sautois, B., Freres, P., Denis, C., Seidel, L., Waltregny, D., & Gennigens, C. (2024). Metastatic reanl cell carcinoma : monocentric retrospective data on first-line treatment. Belgian Journal of Medical Oncology. Peer Reviewed verified by ORBi |
Denis, C., & Sautois, B. (November 2023). Mise au point et stratégies thérapeutiques dans le cancer de la prostate avancé et métastatique. Médecine Nucléaire: Imagerie Fonctionnelle et Métabolique, 47 (6), 300 - 308. doi:10.1016/j.mednuc.2023.09.003 Editorial reviewed |
Unterrainer, L., Farolfi, A., Rosar, F., Denis, C., Emmett, L., de Kouchkovsky, I., Hope, T. A., Hotta, M., Gafita, A., Djaileb, L., Czernin, J., & Calais, J. (01 June 2023). Early changes of PSMA PET signal after initiation of androgen receptor signaling inhibitors in mCRPC: An international multicenter retrospective study [Poster presentation]. ASCO, Chicago, United States. doi:10.1200/jco.2023.41.16_suppl.5063 Peer reviewed |
Troisfontaine, F., Denis, C., Servais, S., Lousberg, L., & Jerusalem, G. (December 2022). Les CAR-T cells dans le traitement des tumeurs solides : où en sommes-nous ? Revue Médicale de Liège, 77 (12), 706 - 709. Editorial Reviewed verified by ORBi |
Denis, C., COUSIN, F., De Laere, B., HUSTINX, R., SAUTOIS, B.* , & WITHOFS, N.*. (21 April 2022). Using, 68Ga-PSMA-11 PET/CT for therapy response assessment in patients with metastatic castration-resistant prostate cancer: an application of EAU/EANM recommendations in clinical practice. Journal of Nuclear Medicine, 63 (12), 1815-1821. doi:10.2967/jnumed.121.263611 Peer Reviewed verified by ORBi * These authors have contributed equally to this work. |
Denis, C., Cousin, F., De Laere, B., Hustinx, R., Sautois, B., & Withofs, N. (2022). Using 68Ga-PSMA-11 PET/CT for therapy response assessment in patients with metastatic castration-resistant prostate cancer : an application of EAU/EANM recommendations in clinical practice [Poster presentation]. BMUC, Belgium. Editorial reviewed |
Sautois, B., & Denis, C. (2022). Le médicament du mois : Apalutamide, Erleada® (2022). Revue Médicale de Liège, 77 (10), 609-615. Editorial Reviewed verified by ORBi |
Colassin, A., Denis, C., HERMESSE, J., WALTREGNY, D., & SAUTOIS, B. (May 2021). Prise en charge d'un cancer de la prostate métastatique au diagnostic. Revue Médicale de Liège, 76 (5-6), 496-501. Peer reviewed |
Denis, C., Sakalihasan, S., FRERES, P., WITHOFS, N., & SAUTOIS, B. (2021). Cemiplimab for cisplatin resistant metastatic penile cancer. Case Reports in Oncology, 14, 972-976. doi:10.1159/000517008 Peer Reviewed verified by ORBi |
Denis, C., & Bustin, F. (March 2020). A Patient with BRAFV600E - Mutant Lung Adenocarcinoma Responding to Dabrafenib and Trametinib. Clinical case reports international, 4 (1147). Peer reviewed |
Denis, C., Magotteaux, S., Seghaye, M.-C., & NYAMUGABO MUNYERE NKANA, K. (March 2017). Spectrum of clinical manifestations due to mycoplasma pneumoniae infections in children. Belgian Journal of Paediatrics, 19 (1), 64. Peer Reviewed verified by ORBi |
Denis, C., JADOT, V., BOUQUEGNEAU, A., & Krzesinski, J.-M. (September 2016). The Case : Acute renal failure and refractory hyponatremia. Kidney International, 90, 713-714. doi:10.1016/j.kint.2016.02.038 Peer Reviewed verified by ORBi |